EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies

Roya Shafiei, Alaa Alhayek, Lukas Hiller, Lorenz Latta, Tobias Neu, Ahmad Aljohmani iD, Sahar Abdollahibiroun, Eva-Maria Schönborn, Daniela Yildiz, Nicole Schneider-Daum, Claus-Michael Lehr iD, Jörg Haupenthal und 1 weitere

ACS Infectious Diseases · 08.05.2026 · 12 (5) · 1611-1626

DOI: 10.1021/acsinfecdis.5c00915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 10.04.2026. Verfasst von Roya Shafiei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Bacterial Proteins, Pseudomonas Infections, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, Administration for Strategic Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa, a major cause of pulmonary infections, poses significant clinical challenges due to its virulence and rising antimicrobial resistance. We investigated the role of LasB, a key virulence factor and elastase of P. aeruginosa, in disrupting the lung epithelial barrier. LasB cleaves the junctional protein E-cadherin, alters Claudin-4 localization, and reduces levels of immunomodulatory cytokines including GM-CSF and G-CSF. Using bronchial and alveolar cell models, we demonstrate that LasB induces dose-dependent barrier damage in both systems. Transcriptomic analysis reveals widespread gene expression changes, including the upregulation of DUSP2 and FGFBP1 associated with stress signaling and immune modulation. LasB inhibitors mitigate barrier disruption and partially restore cytokine levels. In a live bacterial infection model, LasB inhibition supports antibiotic treatment, enhancing bacterial clearance and preserving epithelial integrity. These findings establish LasB as a pivotal factor in P. aeruginosa pathogenesis and highlight the therapeutic potential of antivirulence strategies targeting LasB as promising adjuncts to conventional antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaBacterial ProteinsPseudomonas InfectionsLungSerine EndopeptidasesHumansAnimalsAnti-Bacterial AgentsEpithelial CellsGene Expression ProfilingMetalloendopeptidases

Stichwörter der Autor:innen

DUSP2FGFBP1LasBPseudomonas aeruginosaantivirulence therapiestight junctions

Substanzen

pseudolysin, Pseudomonas aeruginosaBacterial ProteinsAnti-Bacterial AgentsSerine EndopeptidasesMetalloendopeptidases

Autor:innen und Institutionen

  • Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany.
  • Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, 38124 Braunschweig, Germany.
  • Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany.
  • PharmaScienceHub (PSH), Campus A2.3, 66123 Saarbrücken, Germany.
  • German Center for Infection Research (DZIF), Inhoffenstraße 7, 38124 Braunschweig, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, PZMS, ZHMB, Saarland University, Kirrbergerstraße 100, 66421 Homburg/Saar, Germany.

ORCID-Profile: Ahmad Aljohmani, Claus-Michael Lehr, Anna K H Hirsch

Förderung

  • Bundesministerium für Bildung und Forschung
  • Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
  • Administration for Strategic Preparedness and Response
  • Wellcome
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Shafiei, R., Alhayek, A., Hiller, L., Latta, L., Neu, T., Aljohmani, A., Abdollahibiroun, S., Schönborn, E. M., Yildiz, D., Schneider-Daum, N., Lehr, C. M., Haupenthal, J., & Hirsch, A. K. H. (2026). Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies. ACS Infectious Diseases, 12(5), 1611-1626. https://doi.org/10.1021/acsinfecdis.5c00915

Vancouver

Shafiei R, Alhayek A, Hiller L, Latta L, Neu T, Aljohmani A, et al. Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies. ACS Infectious Diseases. 2026;12(5):1611-1626. doi:10.1021/acsinfecdis.5c00915

BibTeX
@article{Shafiei2026,
  author = {Shafiei, Roya and Alhayek, Alaa and Hiller, Lukas and Latta, Lorenz and Neu, Tobias and Aljohmani, Ahmad and Abdollahibiroun, Sahar and Schönborn, Eva-Maria and Yildiz, Daniela and Schneider-Daum, Nicole and Lehr, Claus-Michael and Haupenthal, Jörg and Hirsch, Anna K H},
  title = {Exploring the Role of Pseudomonas aeruginosa Elastase in Lung Epithelial Barrier Dysfunction: Advancing toward Antivirulence Therapies},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {1611--1626},
  doi = {10.1021/acsinfecdis.5c00915}
}
Kostenlos starten →